800 px horizontal logo.png
CORRECTION - Elevai Labs Inc.
14 nov. 2024 14h35 HE | Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14 nov. 2024 09h08 HE | Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14 nov. 2024 08h10 HE | ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
Zealand Logo (1).png
Zealand Pharma to participate in the Jefferies London Healthcare Conference
13 nov. 2024 12h00 HE | Zealand Pharma
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078),...
Fractyl-Logo.png
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 16h05 HE | Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
kailera logo.png
Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer
12 nov. 2024 08h00 HE | Kailera Therapeutics, Inc.
Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
Rani-Logo.jpg
Rani Therapeutics to Participate in Upcoming Investor Conferences
07 nov. 2024 16h05 HE | Rani Therapeutics, LLC
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05 nov. 2024 07h00 HE | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
Biologic Pharmamedical™ Reveals Capryl-Butyrate™ and necessary lifestyle changes for natural solutions for Gut Health, Mental Clarity, and Age-Defying Wellness
04 nov. 2024 17h29 HE | Biologic Pharmamedical Inc.
This unveils the crucial role of a balanced microbiome in boosting immunity, metabolism, & mental clarity. Discover how gut health impacts longevity.
Fractyl-Logo.png
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
04 nov. 2024 16h05 HE | Fractyl Health, Inc.
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable...